Washington University Center for Kidney Disease Research
华盛顿大学肾脏疾病研究中心
基本信息
- 批准号:8097979
- 负责人:
- 金额:$ 95.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-03 至 2013-05-31
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAcute Kidney FailureAreaBasic ScienceBiomedical ResearchChronic Kidney FailureCitiesClinicalClinical ResearchDevelopmentDiagnosisDiseaseDisease modelFeasibility StudiesFunctional disorderFundingGoalsGrantInterdisciplinary StudyInternationalKidneyKidney DiseasesKidney TransplantationLeadMaintenanceMedicalMonitorNephrologyOrganization administrative structuresOrganogenesisPatientsPlayRenal dialysisResearchResearch PersonnelResourcesRoleSiteTraining ProgramsTranslational ResearchTranslationsUnited States National Institutes of HealthUniversitiesWashingtonbasebenefit sharinginnovationprogramsranpirnase
项目摘要
DESCRIPTION, OVERALL (provided by applicant):
The overarching goal of the Washington University WU Center for Kidney Disease Research (CKDR) is to support centralized resources, facilities, and expertise shared by investigators at WU in order to delineate fundamental mechanisms of renal disease and to facilitate translation of such discoveries to its treatment. This grant fits well within the mandate for NIH O'Brien Centers which is to attract new scientific expertise into the study of the basic mechanisms of kidney diseases and disorders; to encourage multidisciplinary research focused on the causes of these diseases; to explore new basic areas with translational potential; and to generate Developmental Research (DR)/Pilot and Feasibility (P&F) studies which should lead to new and innovative approaches to study kidney disease. We believe WU to be an oustanding site for a George M. OBrien P30 Center for a host of reasons: 1) WU is the 4th largest recipient of NIH funding; 2) Research relevant to kidney disease at WU far antedates the creation of the Renal Division or the concept of a medical subspecialty of nephrology; 3) WU played a major role in the development of the nephrology subspecialty in the USA; WU has a substantial base of ongoing, independently supported high quality basic and clinical research aimed at the pathophysiology, diagnosis, monitoring and treatment of kidney disease that has benefited and will benefit from shared resources; A good deal of the of ongoing, independently supported high quality basic and clinical research is based in the WU Renal Division, but at least as much is based outside of WU Renal; 6) A significant part of the 'outside' research base was attracted to the study of kidney disease by the WU George M. O'Brien Center (1992-2003) and by maintenance of one of its Core Centers by the WU Renal Division since 2003; 7) WU Renal has a training program that dates from 1956 & has been NIH-funded since 1961; 8) WU has one of the oldest renal transplantation programs in the USA dating from 1963; 9) The WU Renal Division owns operates and staffs exclusively one of the largest chronic kidney disease and dialysis practices in the Midwest the patients of which participate frequently in clinical studies; 10) WU is a site on ongoing NIH funded clinical trails relating to management of acute renal failure, chronic renal failure and renal transplantation. The CKDR will be an identifiable organizational unit within WU and will have close ties through shared users and common goals with broad and diverse established centers already in place. The CKDR will consist of an Administrative Core and 3 Biomedical Research Cores. Each Biomedical Research Core will have an extended research base. Two (Renal Organogenesis Core & Renal Disease Models Core) will be International in scope. One (Kidney Translational Research Core) will be a regional St. Louis city-wide Core based at WU and also via subcontract at St. Louis' other academic medical center, St. Louis University.
描述,总体(由申请人提供):
华盛顿大学WU肾脏疾病研究中心(CKDR)的总体目标是支持WU研究人员共享的集中资源,设施和专业知识,以描述肾脏疾病的基本机制,并促进将这些发现转化为治疗的基本机制。这笔赠款非常适合NIH O'Brien中心的任务,这是吸引新的科学专业知识来研究肾脏疾病和疾病的基本机制;鼓励多学科研究重点关注这些疾病的原因;探索具有转化潜力的新基本领域;并产生发展研究(DR)/飞行员和可行性(P&F)研究,这些研究应导致研究肾脏疾病的新方法。我们认为Wu是George M. Obrien P30中心的驱逐场所,原因有很多:1)WU是NIH资助的第四大接受者; 2)与Wu远高于肾脏疾病有关的研究是肾脏分裂的创建或肾脏科医学专业的概念; 3)WU在美国的肾脏科体系的发展中发挥了重要作用;吴具有持续的,独立支持的高质量基础和临床研究的基础,旨在对肾脏疾病的病理生理,诊断,监测和治疗,这些肾脏疾病受益,并将从共享资源中受益;大量正在进行的,独立的高质量基础和临床研究基于吴肾部门,但至少在吴肾脏之外的基于王室。 6)自2003年以来,Wu George M. O'Brien Center(1992-2003)和维持其核心中心之一的肾脏疾病研究了“外部”研究基础的很大一部分。 7)WU肾脏的培训计划可追溯到1956年,自1961年以来一直获得NIH资助; 8)WU是美国最古老的肾移植计划之一,其历史可追溯到1963年; 9)WU肾部门拥有手术,工作人员仅是中西部患者经常参加临床研究的患者中最大的慢性肾脏疾病和透析做法之一。 10)WU是一个正在进行的NIH资助的临床步道,与急性肾衰竭,慢性肾衰竭和肾移植有关的临床步道。 CKDR将是WU内的一个可识别的组织部门,并通过共享用户和共同的目标与已建立的广泛和多样化的中心建立联系。 CKDR将由行政核心和3个生物医学研究核心组成。每个生物医学研究核心将具有扩展的研究基础。两个(肾脏器官核心和肾脏疾病模型核心)将是国际范围。一个(肾脏翻译研究核心)将是位于吴的区域圣路易斯城市核心,也是圣路易斯大学其他学术医学中心的分包。
项目成果
期刊论文数量(57)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Xenotransplantation of embryonic pig kidney or pancreas to replace the function of mature organs.
- DOI:10.1155/2011/501749
- 发表时间:2011
- 期刊:
- 影响因子:2.5
- 作者:Hammerman MR
- 通讯作者:Hammerman MR
Myocardial effects of VDR activators in renal failure.
- DOI:10.1016/j.jsbmb.2010.03.026
- 发表时间:2010-07
- 期刊:
- 影响因子:4.1
- 作者:Mizobuchi, Masahide;Nakamura, Hironori;Tokumoto, Masanori;Finch, Jane;Morrissey, Jeremiah;Liapis, Helen;Slatopolsky, Eduardo
- 通讯作者:Slatopolsky, Eduardo
Targeted exome sequencing integrated with clinicopathological information reveals novel and rare mutations in atypical, suspected and unknown cases of Alport syndrome or proteinuria.
- DOI:10.1371/journal.pone.0076360
- 发表时间:2013
- 期刊:
- 影响因子:3.7
- 作者:Chatterjee R;Hoffman M;Cliften P;Seshan S;Liapis H;Jain S
- 通讯作者:Jain S
Xenotransplantation of pancreatic and kidney primordia-Where do we stand?
- DOI:10.1016/j.trim.2008.10.007
- 发表时间:2009-06-01
- 期刊:
- 影响因子:1.5
- 作者:Hammerman, Marc R.
- 通讯作者:Hammerman, Marc R.
Engraftment of cells from porcine islets of Langerhans following transplantation of pig pancreatic primordia in non-immunosuppressed diabetic rhesus macaques.
将猪胰腺原基移植到非免疫抑制的糖尿病恒河猴中后,猪胰岛细胞的植入。
- DOI:10.4161/org.7.3.16522
- 发表时间:2011
- 期刊:
- 影响因子:2.3
- 作者:Rogers,SharonA;Tripathi,Piyush;Mohanakumar,Thalachallour;Liapis,Helen;Chen,Feng;Talcott,MichaelR;Faulkner,Chad;Hammerman,MarcR
- 通讯作者:Hammerman,MarcR
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marc Randall Hammerman其他文献
Marc Randall Hammerman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marc Randall Hammerman', 18)}}的其他基金
Washington University Center for Kidney Disease Research
华盛顿大学肾脏疾病研究中心
- 批准号:
7883824 - 财政年份:2009
- 资助金额:
$ 95.16万 - 项目类别:
Washington University Center for Kidney Disease Research
华盛顿大学肾脏疾病研究中心
- 批准号:
7325292 - 财政年份:2007
- 资助金额:
$ 95.16万 - 项目类别:
Washington University Center for Kidney Disease Research
华盛顿大学肾脏疾病研究中心
- 批准号:
7869426 - 财政年份:2007
- 资助金额:
$ 95.16万 - 项目类别:
Washington University Center for Kidney Disease Research
华盛顿大学肾脏疾病研究中心
- 批准号:
7480261 - 财政年份:2007
- 资助金额:
$ 95.16万 - 项目类别:
Washington University Center for Kidney Disease Research
华盛顿大学肾脏疾病研究中心
- 批准号:
7635783 - 财政年份:2007
- 资助金额:
$ 95.16万 - 项目类别:
CORE--ORGAN CULTURE AND TISSUE PROCESSING FACILITY
核心——器官培养和组织处理设施
- 批准号:
6314078 - 财政年份:2000
- 资助金额:
$ 95.16万 - 项目类别:
相似国自然基金
抑制MBD2通过下调Rac1和Pcbp2保护脓毒症AKI的机制研究
- 批准号:81870475
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
Gasdermin家族蛋白介导的细胞程序性坏死在急性肾衰竭中的作用
- 批准号:81700596
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
基于腺苷相关蛋白同步化表达探讨缺血预适应保护急性肾功能衰竭的分子机制
- 批准号:81200540
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
生物人工肾小管治疗ARF/MODS的免疫调节作用
- 批准号:30570862
- 批准年份:2005
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Randomized ESRD Trial COmparing CBT alone VERsus with buprenorphine (RECOVER)
单独 CBT 与丁丙诺啡比较的随机 ESRD 试验(恢复)
- 批准号:
10614763 - 财政年份:2022
- 资助金额:
$ 95.16万 - 项目类别:
The Southeastern Acute Kidney Injury (SEAK) Alliance for the COPE-AKI Consortium
COPE-AKI 联盟东南部急性肾损伤 (SEAK) 联盟
- 批准号:
10451665 - 财政年份:2021
- 资助金额:
$ 95.16万 - 项目类别:
Biomarkers for acute interstitial nephritis in humans
人类急性间质性肾炎的生物标志物
- 批准号:
10624302 - 财政年份:2021
- 资助金额:
$ 95.16万 - 项目类别:
The Southeastern Acute Kidney Injury (SEAK) Alliance for the COPE-AKI Consortium
COPE-AKI 联盟东南部急性肾损伤 (SEAK) 联盟
- 批准号:
10296585 - 财政年份:2021
- 资助金额:
$ 95.16万 - 项目类别:
Biomarkers for acute interstitial nephritis in humans
人类急性间质性肾炎的生物标志物
- 批准号:
10402806 - 财政年份:2021
- 资助金额:
$ 95.16万 - 项目类别: